Agilent Registers Facility with FDA as Medical Device Establishment | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent said today it has registered its 80,000 square-foot manufacturing facility in Cedar Creek, Texas, with the US Food and Drug Administration as a medical device establishment.

The registration is required for manufacturing diagnostic products, which the Santa Clara, Calif.-based firm said it intends to develop.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: system to track intron gains and losses, role of RUNX during mitosis, and more.

French officials release a report and move to strength safety measures for clinical trials, ScienceInsider reports.

Researchers find different molecular signatures in cancers from men as compared to those from women, the Wall Street Journal reports.

Researchers trace the deaths of a pair of newborn siblings to a mutation in their LIPT1 genes through whole-exome sequencing, Stat News reports.